Central to Lantheus’ success is PYLARIFY, its flagship product for prostate cancer imaging. Analysts project PYLARIFY sales to reach $1.056 billion in 2024, representing a 23.6% year-over-year ...

Central to Lantheus’ success is PYLARIFY, its flagship product for prostate cancer imaging. Analysts project PYLARIFY sales to reach $1.056 billion in 2024, representing a 23.6% year-over-year ...

The company’s key products include PYLARIFY, a PET imaging agent for prostate cancer, and DEFINITY, an ultrasound contrast agent for cardiac imaging. Lantheus Holdings, Inc. (NASDAQ:LNTH ...

and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. Receive News & Ratings for Lantheus Daily - Enter your email ...

To avoid delays, we encourage participants to Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in ...

Earlier this year, it also formed a partnership with Novartis to pair its PSMA imaging agent Pylarify (piflufolastat F18) diagnostic, with the Swiss pharma's prostate cancer radiotherapy Pluvicto ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...